AbCellera Biologics Inc. Deferred Tax Assets, Deferred Income
AbCellera Biologics Inc. (ABCL) had Deferred Tax Assets, Deferred Income of $21.24 million as of 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2024-02-20
- 2023-12-31: Deferred Tax Assets, Deferred Income $21.24M.
- 2022-12-31: Deferred Tax Assets, Deferred Income $6.04M.
- 2021-12-31: Deferred Tax Assets, Deferred Income $4.77M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2023-12-31 | $21.24M 10-K · filed 2024-02-20 |
| 2022-12-31 | $6.04M 10-K · filed 2024-02-20 |
| 2021-12-31 | $4.77M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |